Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cyclerion Therapeutics (CYCN) Enterprise Value (2019 - 2025)

Cyclerion Therapeutics has reported Enterprise Value over the past 7 years, most recently at -$4.6 million for Q3 2025.

  • Quarterly results put Enterprise Value at -$4.6 million for Q3 2025, down 59.05% from a year ago — trailing twelve months through Sep 2025 was -$4.6 million (down 59.05% YoY), and the annual figure for FY2024 was -$3.2 million, up 57.31%.
  • Enterprise Value for Q3 2025 was -$4.6 million at Cyclerion Therapeutics, down from -$3.0 million in the prior quarter.
  • Over the last five years, Enterprise Value for CYCN hit a ceiling of -$2.9 million in Q3 2024 and a floor of -$70.4 million in Q2 2021.
  • Median Enterprise Value over the past 5 years was -$7.6 million (2023), compared with a mean of -$20.6 million.
  • Biggest five-year swings in Enterprise Value: soared 82.57% in 2023 and later crashed 59.05% in 2025.
  • Cyclerion Therapeutics' Enterprise Value stood at -$54.0 million in 2021, then soared by 75.2% to -$13.4 million in 2022, then soared by 43.42% to -$7.6 million in 2023, then soared by 57.31% to -$3.2 million in 2024, then plummeted by 41.34% to -$4.6 million in 2025.
  • The last three reported values for Enterprise Value were -$4.6 million (Q3 2025), -$3.0 million (Q2 2025), and -$3.6 million (Q1 2025) per Business Quant data.